AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18361280 — intervention group
Group type: EXPERIMENTAL
Intervention: Family approaches
Number of subjects: 0
Study 18361280 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapies
Number of subjects: 0
Study 18361280 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin and calcium supplements
Number of subjects: 0
Study 18361280 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepubertal anorexic patients
Number of subjects: 0
Study 18361280 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-early-onset anorexia nervosa
Number of subjects: 0
Study 16061893 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid magnetic resonance imaging (rMRI)
Number of subjects: 0
Study 16061893 — intervention group
Group type: COMPARATOR
Intervention: Normal distribution
Number of subjects: 0
Study 16061893 — intervention group
Group type: COMPARATOR
Intervention: Gamma distribution
Number of subjects: 0
Study 16061893 — intervention group
Group type: EXPERIMENTAL
Intervention: Lognormal distribution
Number of subjects: 0
Study 12374237 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation
Number of subjects: 230
Study 12374237 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 230
Study 10404864 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 30
Study 10404864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7750585 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot leuprolide acetate (3.75 mg JM depot LA given every month and daily placebo tablets)
Number of subjects: 12
Study 7750585 — intervention group
Group type: COMPARATOR
Intervention: Danazol (800 mg oral danazol daily with a monthly placebo injection)
Number of subjects: 12
Study 2111189 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-tocainide
Number of subjects: 6
Study 2111189 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-tocainide
Number of subjects: 6
Study 7270842 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms fentanyl/kg body weight
Number of subjects: 16
Study 7270842 — intervention group
Group type: COMPARATOR
Intervention: 0.5-1.0% halothane
Number of subjects: 16
Study 31480900 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache specialists with migraine
Number of subjects: 0
Study 31480900 — intervention group
Group type: EXPERIMENTAL
Intervention: General neurologists
Number of subjects: 0
Study 31480900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain specialists
Number of subjects: 0
Study 31480900 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners
Number of subjects: 0
Study 31480900 — intervention group
Group type: COMPARATOR
Intervention: General population (age- and sex-matched)
Number of subjects: 0
Study 31480900 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologists
Number of subjects: 0
Study 31480900 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache specialists
Number of subjects: 0
Study 30657531 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plate system (n=65)
Number of subjects: 296
Study 30657531 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging external fixation (n=64)
Number of subjects: 296
Study 30657531 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous pinning (n=58)
Number of subjects: 296
Study 30657531 — intervention group
Group type: COMPARATOR
Intervention: Casting (n=117)
Number of subjects: 296
Study 30657531 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation (n=64)
Number of subjects: 296
Study 28711423 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor system intervention
Number of subjects: 171
Study 28711423 — intervention group
Group type: COMPARATOR
Intervention: Usual care (comparison group)
Number of subjects: 171
Study 25809579 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment for 1 year
Number of subjects: 104
Study 25809579 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (meta-analysis of eight trials)
Number of subjects: 104
Study 23650431 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg nebulized furosemide
Number of subjects: 100
Study 23650431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21869624 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-m repeated sprint training (TG)
Number of subjects: 20
Study 21869624 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study 19595037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) group (5 minutes of ischemia followed by 5 minutes of reperfusion)
Number of subjects: 48
Study 19595037 — intervention group
Group type: COMPARATOR
Intervention: Control group (received Pringle's maneuver, no ischemic preconditioning)
Number of subjects: 48
Study 19595037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IP and Control)
Number of subjects: 48
Study 17456554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water irrigation
Number of subjects: 715
Study 17456554 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline irrigation
Number of subjects: 715
Study 15521273 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced surface ablation (PASA) using Nidek EC-5000 laser
Number of subjects: 17
Study 11558026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation
Number of subjects: 13
Study 11558026 — intervention group
Group type: COMPARATOR
Intervention: Vasoconstrictive treatment (vasopressin/terlipressin)
Number of subjects: 13
Study 11558026 — intervention group
Group type: COMPARATOR
Intervention: Vasoactive treatment (somatostatin/octreotide)
Number of subjects: 13
Study 11558026 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 13
Study 9761517 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (ER tablets, 10 mg)
Number of subjects: 79
Study 9761517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 7834862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF) platelets
Number of subjects: 0
Study 7834862 — intervention group
Group type: COMPARATOR
Intervention: Normal cells (control)
Number of subjects: 0
Study 7834862 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygote individuals
Number of subjects: 0
Study 7834862 — intervention group
Group type: COMPARATOR
Intervention: Cystic fibrosis (CF) platelets and control platelets
Number of subjects: 0
Study 3341541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric infusion of sodium hydroxide
Number of subjects: 166
Study 3341541 — intervention group
Group type: COMPARATOR
Intervention: Intragastric infusion of saline solution or hydrochloric acid
Number of subjects: 166
Study 3341541 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative test results
Number of subjects: 166
Study 3341541 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive test results
Number of subjects: 166
Study 31070072 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer, far-far-near-near (FFNN) unlocked technique
Number of subjects: 138
Study 31070072 — intervention group
Group type: COMPARATOR
Intervention: Single-layer continuous locked (SLL) technique
Number of subjects: 138
Study 29753800 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual intercourse
Number of subjects: 12
Study 29753800 — intervention group
Group type: COMPARATOR
Intervention: Abstinence from sexual intercourse
Number of subjects: 12
Study 27391830 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning applied on the upper extremity for three cycles on postoperative days 1, 5, and 12.
Number of subjects: 30
Study 27391830 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Number of subjects: 30
Study 24861558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 737
Study 24861558 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term combinations of NRT
Number of subjects: 737
Study 24861558 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 737
Study 24861558 — intervention group
Group type: EXPERIMENTAL
Intervention: All pharmacotherapies
Number of subjects: 737
Study 22867074 — intervention group
Group type: EXPERIMENTAL
Intervention: Kids Nutrition and Fitness program (6-week nutrition and physical activity educational after-school program)
Number of subjects: 251
Study 20056003 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 40,000 IU per week (DD group)
Number of subjects: 421
Study 20056003 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 20,000 IU per week (DP group)
Number of subjects: 421
Study 20056003 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PP group)
Number of subjects: 421
Study 18684793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 16
Study 18684793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17520505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (AChE-I) including donepezil, galantamine, and rivastigmine
Number of subjects: 100
Study 17520505 — intervention group
Group type: COMPARATOR
Intervention: Cholinesterase inhibitors (AChE-I)
Number of subjects: 100
Study 14560174 — intervention group
Group type: EXPERIMENTAL
Intervention: QD (10 mg of Adderall at 7:30 a.m. and placebo at noon)
Number of subjects: 12
Study 14560174 — intervention group
Group type: EXPERIMENTAL
Intervention: BID (10 mg of Adderall at 7:30 a.m. and at noon)
Number of subjects: 12
Study 10881557 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondeontic versions of the Wason selection task
Number of subjects: 0
Study 10881557 — intervention group
Group type: COMPARATOR
Intervention: Deontic contexts
Number of subjects: 0
Study 9101392 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 1323
Study 8226444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient [Hb] of 15.9 ± 0.7 g/100 ml breathing 21 or 12% O2
Number of subjects: 7
Study 8226444 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased [Hb] to 13.8 ± 0.6 g/100 ml by venesection and isovolemic replacement with 5% albumin in 0.9% saline
Number of subjects: 7
Study 8226444 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased [Hb] to 13.8 ± 0.6 g/100 ml
Number of subjects: 7
Study 3711026 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine
Number of subjects: 58
Study 3711026 — intervention group
Group type: COMPARATOR
Intervention: Thiothixene
Number of subjects: 58
Study 3711026 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine and Thiothixene
Number of subjects: 58
Study 29101521 — intervention group
Group type: EXPERIMENTAL
Intervention: Transducer frequency set at 1.7/3.3 MHz
Number of subjects: 22
Study 29101521 — intervention group
Group type: COMPARATOR
Intervention: Transducer frequency set at 1.5/3.0 MHz
Number of subjects: 22
Study 26694209 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexemic acid (1 g) administered after induction
Number of subjects: 50
Study 26694209 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tranexemic acid)
Number of subjects: 50
Study 24036634 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) for 12 weeks with peg-interferon/ribavirin (peg-IFN/RBV) for 48 weeks
Number of subjects: 74
Study 24036634 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus peg-interferon/ribavirin (peg-IFN/RBV)
Number of subjects: 74
Study 24036634 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-interferon/ribavirin (peg-IFN/RBV) regimen
Number of subjects: 74
Study 24036634 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-PRO
Number of subjects: 74
Study 22746973 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (PSL) plus the LTRA pranlukast (PRL) for 2 weeks
Number of subjects: 23
Study 22746973 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (PSL) alone
Number of subjects: 23
Study 20144246 — intervention group
Group type: EXPERIMENTAL
Intervention: L. plantarum MF1298 (10^10 CFU)
Number of subjects: 16
Study 20144246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18716499 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low back pain (CLBP) patients
Number of subjects: 103
Study 18716499 — intervention group
Group type: COMPARATOR
Intervention: Pain-free individuals
Number of subjects: 103
Study 15889583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group treatment (CBGT) administered over 8, 90 min weekly sessions
Number of subjects: 19
Study 15889583 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (wait list)
Number of subjects: 19
Study 15552855 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily toothbrushing under supervision of trained teacher
Number of subjects: 0
Study 15552855 — intervention group
Group type: COMPARATOR
Intervention: Daily toothbrushing under supervision of parents
Number of subjects: 0
Study 10544378 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at an initial dose of 0.125 U/kg/week for the first month, then 0.25 U/kg/week
Number of subjects: 20
Study 10544378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8688278 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid-hydroxyethylstarch combination (lactated Ringer's solution 1000 ml with up to 1000 ml of 6% hydroxyethylstarch)
Number of subjects: 90
Study 8688278 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid without crystalloid (up to 1000 ml of 6% hydroxyethylstarch)
Number of subjects: 90
Study 8688278 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid-gelatin combination (lactated Ringer's solution 1000 ml with up to 1000 ml of modified gelatin)
Number of subjects: 90
Study 1852912 — intervention group
Group type: EXPERIMENTAL
Intervention: Various set-up methods for accuracy of field placement
Number of subjects: 20
Study 6664154 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine (100 mg)
Number of subjects: 15
Study 6664154 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (32 mg)
Number of subjects: 15
Study 6664154 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine (100 mg) + Naloxone (8 mg)
Number of subjects: 15
Study 6664154 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine (100 mg) + Naloxone (32 mg)
Number of subjects: 15
Study 6664154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31167726 — intervention group
Group type: EXPERIMENTAL
Intervention: CMA group
Number of subjects: 27
Study 30103851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate-partner violence (using the Composite Abuse Scale)
Number of subjects: 0
Study 27243803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 0.3, 2, or 10 mg/kg intravenously every 3 weeks
Number of subjects: 168
Study 27243803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (treated beyond progression)
Number of subjects: 168
Study 25455429 — intervention group
Group type: EXPERIMENTAL
Intervention: High task control (compared to neutral)
Number of subjects: 110
Study 25455429 — intervention group
Group type: EXPERIMENTAL
Intervention: High task control (compared to low)
Number of subjects: 110
Study 25455429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low task control
Number of subjects: 110
Study 25455429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low task control effects
Number of subjects: 110
Study 25455429 — intervention group
Group type: COMPARATOR
Intervention: Neutral task control
Number of subjects: 110
Study 25455429 — intervention group
Group type: EXPERIMENTAL
Intervention: High task control
Number of subjects: 110
Study 23034262 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (prostaglandin E) administration during surgery
Number of subjects: 0
Study 23034262 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alprostadil)
Number of subjects: 0
Study 20452186 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sagittal split osteotomies (BSSO)
Number of subjects: 23
Study 20452186 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular distraction osteogenesis (MDO)
Number of subjects: 23
Study 18035291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spine flexed (Group F)
Number of subjects: 33
Study 18035291 — intervention group
Group type: COMPARATOR
Intervention: Lumbar spine in neutral position (Group N)
Number of subjects: 33
Study 15111966 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal resection with lowest percent of purulent complications
Number of subjects: 589
Study 15111966 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential approach to choice of resection or extirpation method
Number of subjects: 589
Study 12460130 — intervention group
Group type: EXPERIMENTAL
Intervention: MET/CBT5 (6-week intervention with 2 sessions of individual motivational enhancement therapy plus 3 sessions of group cognitive behavioral therapy)
Number of subjects: 0
Study 12460130 — intervention group
Group type: EXPERIMENTAL
Intervention: MET/CBT12 (12-week intervention with 2 sessions of motivational enhancement therapy plus 10 sessions of group cognitive behavioral therapy)
Number of subjects: 0
Study 12460130 — intervention group
Group type: EXPERIMENTAL
Intervention: MET/CBT12 + FSN (12-week intervention with MET/CBT12 plus family support network)
Number of subjects: 0
Study 12460130 — intervention group
Group type: EXPERIMENTAL
Intervention: ACRA (12-week intervention based on adolescent community reinforcement approach)
Number of subjects: 0
Study 12460130 — intervention group
Group type: EXPERIMENTAL
Intervention: MDFT (multi-dimensional family therapy)
Number of subjects: 0
Study 18314570 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention, nutrition counseling, home safety assessment, smoking and alcohol interventions for at-risk subjects.
Number of subjects: 100
Study 8612440 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic intermittent intravenous insulin therapy (CIIIT)
Number of subjects: 26
Study 8612440 — intervention group
Group type: COMPARATOR
Intervention: Control phase (no CIIIT)
Number of subjects: 26
Study 2682969 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid combination (group A)
Number of subjects: 82
Study 2682969 — intervention group
Group type: COMPARATOR
Intervention: Penicillin, aminoside, and metronidazole combination (group B)
Number of subjects: 82
Study 4830231 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ileal absorption of chenodeoxycholic acid
Number of subjects: 12
Study 4830231 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ileal absorption of glycochenodeoxycholic acid
Number of subjects: 12
Study 4830231 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ileal absorption of taurocholic acid
Number of subjects: 12
Study 4830231 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive permeability of the jejunum to bile acids
Number of subjects: 12
Study 4830231 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of absorption rates
Number of subjects: 12
Study 4830231 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect of intraluminal pH on jejunal uptake
Number of subjects: 12
Study 31154601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (implementation intentions)
Number of subjects: 60
Study 31154601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention plus booster group (implementation intentions + reminder)
Number of subjects: 60
Study 31154601 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 30124367 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative intervention process (experimental group)
Number of subjects: 18
Study 30124367 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 18
Study 28549278 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 188
Study 25546413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF) diet
Number of subjects: 24
Study 25546413 — intervention group
Group type: COMPARATOR
Intervention: Intermittent fasting (IF) with anti-oxidant (vitamins C and E) supplementation
Number of subjects: 24
Study 23182924 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary counselling during pregnancy and breastfeeding
Number of subjects: 0
Study 23182924 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's dietary fatty acid intake
Number of subjects: 0
Study 23182924 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counselling)
Number of subjects: 0
Study 22696911 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 62
Study 22696911 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 62
Study 22696911 — intervention group
Group type: EXPERIMENTAL
Intervention: Both beta blockers (Carvedilol and Propranolol)
Number of subjects: 62
Study 19046483 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD subjects off medication for 24 hours
Number of subjects: 52
Study 19046483 — intervention group
Group type: COMPARATOR
Intervention: ADHD subjects on medication
Number of subjects: 52
Study 17218764 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA‐VitC (1.6 g ASA + 0.96 g Vit C/day)
Number of subjects: 10
Study 17218764 — intervention group
Group type: COMPARATOR
Intervention: ASA (1.6 g ASA/day)
Number of subjects: 10
Study 17218764 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA
Number of subjects: 10
Study 17218764 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA and ASA‐VitC
Number of subjects: 10
Study 17218764 — intervention group
Group type: EXPERIMENTAL
Intervention: MKN‐45 cells incubated with ASA
Number of subjects: 10
Study 17218764 — intervention group
Group type: EXPERIMENTAL
Intervention: MKN‐45 cells incubated with ASA‐VitC
Number of subjects: 10
Study 10588398 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold right unilateral or bilateral ECT
Number of subjects: 268
Study 8720309 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium suppositories
Number of subjects: 12
Study 8720309 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of commercial enteric coated tablet
Number of subjects: 12
Study 2010637 — intervention group
Group type: EXPERIMENTAL
Intervention: 566C80 3000 mg once daily for 12 days
Number of subjects: 20